Navigation Links
Amarin Announces Initiation of Cardiovascular Development Strategy
Date:10/10/2007

Capitalizing on Known Therapeutic Benefits of Unsaturated Fatty Acids in

Cardiovascular Disease

LONDON, October 10 /PRNewswire-FirstCall/ -- Amarin Corporation plc (NASDAQ: AMRN) today announced that it has initiated a cardiovascular development strategy to capitalize on the known therapeutic benefits of unsaturated fatty acids in cardiovascular disease. Amarin plans to utilize its extensive know-how and experience in lipid science to develop a series of products targeting the vascular system, endothelial dysfunction and vascular re-modeling.

Dr. Declan Doogan, Amarin's President of Research and Development commented "Building on an extensive knowledge base in cardiovascular disease, we plan to leverage our expertise in lipid science to create new therapies from our existing family of compounds. We are fortunate to have the know-how, the resources and the ability to draw on an extensive knowledge network in cardiovascular disease."

Rick Stewart, Chief Executive Officer, commented "While neurology remains Amarin's core focus, the new cardiovascular strategy capitalizes on existing assets which already have an established safety and efficacy profile in Japan. Consequently, this is a logical extension from Amarin's existing therapeutic base for ultra-pure EPA and its derivatives. The expansion of Amarin's therapeutic reach into diseases with a significantly greater prevalence than neurological disease enhances our development portfolio mix and creates added value from our lipid technology platform."

Amarin intends to commence a series of clinical trials with AMR 101 (97% pure EPA) in dyslipidemia, the first of which will commence by the end of this year. In addition, Am
'/>"/>

SOURCE Amarin Corporation Plc
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)LELYSTAD, The Netherlands, December 2 Pepscan Holding NV,the Netherlands based biotechnology company focusing on protein mimicking,technology for the generation of immune therapeutics today announced
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
(Date:12/2/2009)QUEBEC CITY, Dec. 2 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today annou
(Date:12/2/2009)HOBOKEN, N.J., Dec. 2 According to the National Institute of Health, 40 percent to 45 percent of Americans diagnosed with diabetes already have some stage of diabetic retinopathy. Diabetic retinopat
Breaking Biology Technology:Dutch Biotech Company Pepscan Appoints New CEO 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4
...he Wisconsin Technology Council has teamed with Pr... to provide a searchable database of commercial re...sintechnologycouncil.com. The service can be acce...perty Search. , ,This new feature will allow techn...consin the ability to search a wide variety of spa...
...e of the IT industry news rags was making a big de...r players in radio frequency ID tag manufacture. A...ed that some customers were claiming failure rates... suggesting other factors like poor paper quality ...r was rolled up to tightly. , ,Whatever the cause...
...C. Johnson & Son Inc. made the No. 2 spot in the ...04. The top spot in this year,s list of technology...sconsin organzations, other than S.C. Johnson, mad... maintaining the annual list for the past seven ye...y agendas and usage, and examining their business ...
Other Biology Technology:The more things change ... 2The more things change ... 3S.C. Johnson lands in No. 2 spot in Information Week 500 list 2
(Date:12/3/2009)...Dec. 3, 2009) Van Andel Research Institute (VAR...lant hormone abscisic acid (ABA) works at the mole...l stresses such as drought and cold. Their findin...engineer crops that thrive in harsh environments a... The findings could also have implications for str...
(Date:12/3/2009)...erly upset by a social snubbing? Your genetics, no...e long known that opium-like painkillers, called o...ome forms of emotional stress. Now, a new study re...ilig shows that small genetic differences in the g...nsity of people,s responses to social rejection. ...
(Date:12/3/2009)...have measured CO2 levels for the past three years ...ely inhabited rural area near Valladolid. The resu...ian Peninsula, show that the levels rose "signific..., physicists and meteorologists have been trying t...how these have evolved in the troposphere over var...
Breaking Biology News(10 mins):VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3CO2 levels rising in troposphere over rural areas 2Science Coalition commends Presidents strategy for innovation 10011 1Endometrial Ablation Offers Relief for Abnormally Heavy or Irregular Menstrual Bleeding 57880 1Endometrial Ablation Offers Relief for Abnormally Heavy or Irregular Menstrual Bleeding 57880 2Endometrial Ablation Offers Relief for Abnormally Heavy or Irregular Menstrual Bleeding 57880 3VIDEO from Medialink and Siemens 3A Hi Tech Donation Benefits Childrens Health Fund 57878 1
...genome sequence was published. Now, nearly 200 bac...hits the scientific press most weeks. This burgeon...ing,?however. Having all these genome sequences ma...se human disease, how to control their spread, and...mparing genome sequences, scientists can learn muc...
...of a therapeutic cancer vaccine combining the synt... Coley Pharmaceutical), with a peptide antigen wer...igation. The paper shows that the CpG 7909 DNA seq...bility to recognize and destroy cancer cells. The ... of the Ludwig Institute for Cancer Research (LICR...
...ice in field trials in China report higher crop yi...lated health problems, according to a study by res...e University of California, Davis. , Results of t...journal Science. , "This paper studies two of the ...oduction trials, the last step before commercializ...
Other Biology News:Multiple Campylobacter Genomes Sequenced 2Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy 2Genetically modified rice in China benefits farmers' health, study finds 2Genetically modified rice in China benefits farmers' health, study finds 3Genetically modified rice in China benefits farmers' health, study finds 4
IMAGEQUANT 400 WKSTN from GE Healthcare, formerly Amersham Biosciences
Rabbit Anti-Human IFN-Alpha / Beta R2 (IFNAR2) (CD118) Neutralizing Polyclonal Antibody, Unconjugated from PBL InterferonSource
Rabbit Anti-MYCOBACTERIUM TUBERCULOSIS Polyclonal Antibody, Unconjugated from AbD Serotec
ImageQuant 400 from GE Healthcare, formerly Amersham Biosciences
Biology Products: